New York, July 25, 2024 - PRISM MarketView - Today the PRISM NextGen Tech and AI Index leader Predicative Oncology (POAI) announced it will enter the $51.5M biomarker discovery market. This decision to expand their AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology, comes on the heels of positive results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital. These results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. From this study, Predictive Oncology obtained and analyzed data that supports novel ovarian cancer biomarker discovery and development that will be further explored both independently and in partnership with biopharma companies.
“We believe the identification of novel cancer biomarkers represents the next significant opportunity for the application of our platform, which leverages the substantial value inherent in the diversified patient samples and data that we possess, as well as additional potential revenue streams for our company. Our technology has broad applicability, including the development of a clinical decision support tool to screen for clinical trial enrollment, and to inform subsequent drug discovery and development.”
Raymond Vennare, Chief Executive Officer of Predictive Oncology
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities